Species | Target name | Source | Bibliographic reference |
---|---|---|---|
Homo sapiens | ataxin 2 | Starlite/ChEMBL | No references |
Homo sapiens | TAR DNA binding protein | Starlite/ChEMBL | No references |
Mycobacterium tuberculosis | Adenosylmethionine-8-amino-7-oxononanoate aminotransferase BioA | Starlite/ChEMBL | No references |
Species | Potential target | Known druggable target | Length | Alignment span | Identity |
---|---|---|---|---|---|
Mycobacterium leprae | Probable 4-aminobutyrate aminotransferase GabT (GAMMA-AMINO-N-BUTYRATE TRANSAMINASE) (GABA TRANSAMINASE) (GLUTAMATE:SUCCINIC SEM | Adenosylmethionine-8-amino-7-oxononanoate aminotransferase BioA | 437 aa | 397 aa | 28.5 % |
Species | Potential target | Raw | Global | Species |
---|---|---|---|---|
Loa Loa (eye worm) | RNA recognition domain-containing protein domain-containing protein | 0.0076 | 0.32 | 1 |
Trypanosoma brucei | PAB1-binding protein , putative | 0.003 | 0.0276 | 0.5 |
Mycobacterium tuberculosis | Adenosylmethionine-8-amino-7-oxononanoate aminotransferase BioA | 0.0184 | 1 | 1 |
Mycobacterium tuberculosis | Probable aminotransferase | 0.0184 | 1 | 1 |
Trypanosoma cruzi | PAB1-binding protein , putative | 0.003 | 0.0276 | 0.5 |
Loa Loa (eye worm) | RNA binding protein | 0.0076 | 0.32 | 1 |
Brugia malayi | TAR-binding protein | 0.0076 | 0.32 | 1 |
Plasmodium falciparum | ataxin-2 like protein, putative | 0.003 | 0.0276 | 1 |
Brugia malayi | RNA binding protein | 0.0076 | 0.32 | 1 |
Toxoplasma gondii | LsmAD domain-containing protein | 0.003 | 0.0276 | 1 |
Schistosoma mansoni | tar DNA-binding protein | 0.0076 | 0.32 | 1 |
Schistosoma mansoni | tar DNA-binding protein | 0.0076 | 0.32 | 1 |
Trichomonas vaginalis | acetylornithine aminotransferase, putative | 0.0184 | 1 | 0.5 |
Brugia malayi | RNA recognition motif domain containing protein | 0.0076 | 0.32 | 1 |
Schistosoma mansoni | tar DNA-binding protein | 0.0076 | 0.32 | 1 |
Echinococcus granulosus | tar DNA binding protein | 0.0076 | 0.32 | 1 |
Wolbachia endosymbiont of Brugia malayi | acetylornithine transaminase protein | 0.0026 | 0 | 0.5 |
Schistosoma mansoni | tar DNA-binding protein | 0.0076 | 0.32 | 1 |
Echinococcus multilocularis | tar DNA binding protein | 0.0076 | 0.32 | 1 |
Mycobacterium ulcerans | adenosylmethionine-8-amino-7-oxononanoate aminotransferase | 0.0184 | 1 | 1 |
Plasmodium falciparum | ataxin-2 like protein, putative | 0.003 | 0.0276 | 1 |
Brugia malayi | hypothetical protein | 0.003 | 0.0276 | 0.0861 |
Trypanosoma cruzi | PAB1-binding protein , putative | 0.003 | 0.0276 | 0.5 |
Schistosoma mansoni | tar DNA-binding protein | 0.0076 | 0.32 | 1 |
Leishmania major | hypothetical protein, conserved | 0.003 | 0.0276 | 0.5 |
Loa Loa (eye worm) | TAR-binding protein | 0.0076 | 0.32 | 1 |
Chlamydia trachomatis | glutamate-1-semialdehyde-2,1-aminomutase | 0.0026 | 0 | 0.5 |
Mycobacterium ulcerans | hypothetical protein | 0.0184 | 1 | 1 |
Plasmodium vivax | ataxin-2 like protein, putative | 0.003 | 0.0276 | 1 |
Activity type | Activity value | Assay description | Source | Reference |
---|---|---|---|---|
AC50 (functional) | 6.97 uM | PubChem BioAssay. Mycobacterium tuberculosis BioA enzyme inhibitor Measured in Biochemical System Using Plate Reader - 2163-02_Inhibitor_Dose_CherryPick_Activity. (Class of assay: confirmatory) | ChEMBL. | No reference |
Potency (functional) | 6.3096 uM | PubChem BioAssay. qHTS for Inhibitors of ATXN expression. (Class of assay: confirmatory) | ChEMBL. | No reference |
Potency (functional) | 10 uM | PubChem BioAssay. qHTS of TDP-43 Inhibitors. (Class of assay: confirmatory) | ChEMBL. | No reference |
Potency (functional) | 89.1251 uM | PUBCHEM_BIOASSAY: HTS for Inhibitors of HP1-beta Chromodomain Interactions with Methylated Histone Tails. (Class of assay: confirmatory) [Related pubchem assays (depositor defined):AID488962] | ChEMBL. | No reference |
Many chemical entities in TDR Targets come from high-throughput screenings with whole cells or tissue samples, and not all assayed compounds have been tested against a single a single target protein, probably because they get ruled out during screening process. Even if these compounds may have not been of interest in the original screening, they may come as interesting leads for other screening assays. Furthermore, we may be able to propose drug-target associations using chemical similarities and network patterns.